SavedAdd your journal

Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 5

HER-2/neu alterations in non-small cell lung cancer: A comprehensive evaluation by fluorescence in situ hybridization and immunohistochemistry

Zekiye AYDOĞDU
Sait TÜMER
Aydanur KARGI
Sebnem YİLDİRİMCAN KADİCESME
Cigdem Eresen YAZİCİOGLU
Oğuz ALTUNGÖZ
Pages
783–788
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, HER-2/neu overexpression may be associated with transcriptionalmechanisms rather than gene amplification.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The molecular relationships of protein overexpression and HER-2/neu gene amplification in lung cancers are not clearlydefined.
📊
Key Findings & Data:The aim of the study is to evaluate HER-2/neu changes in non-small cell lung cancer with in situ hybridization andimmunohistochemistry, to compare the effectiveness of both methods and to examine the influence of HER-2/neu gene and proteinlevel alterations on prognosis.Material and Methods: HER-2/neu alterations were analyzed with fluorescence in situ hybridization and immunohistochemistry in24 patients with non-small cell lung cancer.Results: Of 24 patients, 13 (54%) were found immunohistochemistry (IHC) positive, on the other hand 24 (100%) were foundfluorescence in situ hybridization (FISH) negative.
💡
Conclusion & Impact:Therefore, HER-2/neu overexpression may be associated with transcriptionalmechanisms rather than gene amplification.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The molecular relationships of protein overexpression and HER-2/neu gene amplification in lung cancers are not clearlydefined. The aim of the study is to evaluate HER-2/neu changes in non-small cell lung cancer with in situ hybridization andimmunohistochemistry, to compare the effectiveness of both methods and to examine the influence of HER-2/neu gene and proteinlevel alterations on prognosis.Material and Methods: HER-2/neu alterations were analyzed with fluorescence in situ hybridization and immunohistochemistry in24 patients with non-small cell lung cancer.Results: Of 24 patients, 13 (54%) were found immunohistochemistry (IHC) positive, on the other hand 24 (100%) were foundfluorescence in situ hybridization (FISH) negative. Balanced trisomy was detected in 23 out of FISH negative cases and balancedquadrisomy was detected in one case. Our study has revealed that overexpression of HER-2/neu protein is not associated with realgene amplification. No significant correlation was detected between HER-2/neu overexpression with amplification, and prognosisof non-small cell lung cancer.Conclusion: No correlation is present between fluorescence in situ hybridization and immunohistochemistry results. HER-2/neualterations are present in non-small cell lung cancers. Therefore, HER-2/neu overexpression may be associated with transcriptionalmechanisms rather than gene amplification.

🔖

Cite This Article

AYDOĞDU, Z., TÜMER, S., KARGI, A., KADİCESME, S. Y., YAZİCİOGLU, C. E., ALTUNGÖZ, O. (2022). HER-2/neu alterations in non-small cell lung cancer: A comprehensive evaluation by fluorescence in situ hybridization and immunohistochemistry. Annals of Medical Research, Cilt: 26 - Sayı: 5, 783–788. https://ajindex.com/articles/447406

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30
  2. Wang D, Pham NA, Tong J, et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer 2017;140:662-73
  3. Sasaki H, Suzuki A, Tatematsu T, et al. Prognosis of recurrent non-small cell lung cancer following complete resection. Oncol Lett 2014;7:1300-4
  4. Iqbal N, Iqbal N, et al. Human epidermal growth factor receptor 2 (HER2) in Cancers: overexpression and therapeutic lmplications. Mol Biol Int 2014;2014:1-9
  5. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34-74
  6. Kobyakov DS, Avdalyan AM, Bobrov IP, et al. Correlation of HER-2/ Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer. Bull Exp Biol Med 2014;157:789-93
  7. Rothschild SI. Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK. Cancers (Basel) 2015;7:930- 49
  8. Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data. J Thorac Oncol 2010;5:1922-32
  9. Rosell R. Toward customized trastuzumab in HER-2/neuoverexpressing non-small-cell lung cancers. J Clin Oncol 2004;22:1171-3
  10. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014;16:R22
  11. Ohashi K, Hotta K, Hirata T, et al. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol. Clin Lung Cancer 2017;18:92-5
  12. Ozer O, Sahin FI, Aydemir F, et al. HER-2 / neu gene amplification in paraffin- embedded tissue sections of meningioma patients meningiom olgular › na ait parafin blok doku kesitlerinde her2 /neu. Turk Neurosurg 2009;19:135-8
  13. Amplification G, Immunohistochemistry W, Ciampa A, et al. HER-2 status in breast cancer. Appl Immunohistochem 2006;14:132-7
  14. Meert AP, Martin B, Verdebout JM, et al. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? Lung Cancer 2005;47:325-36
  15. Pellegrini C, Falleni M, Marchetti A, et al. HER-2 / Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-pcr, Fluorescence in Situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9:3645-52
  16. Tissue T, Winston J, Wiseman S, et al. HER-